Pfizer, Mylan in talks to merge off-patent drugs business

Mylan shareholders would receive a little more than 40 per cent of the newly formed entity, with Pfizer shareholders receiving the remainder, the person said, adding that Pfizer would also get about $12 billion in proceeds from a new sale of debt.

New Delhi: Pfizer Inc is in talks to merge its off-patent drugs business with Mylan NV in a stock deal, according to a source familiar with the matter.

Mylan shareholders would receive a little more than 40 per cent of the newly formed entity, with Pfizer shareholders receiving the remainder, the person said, adding that Pfizer would also get about $12 billion in proceeds from a new sale of debt.

Separation of Pfizer's off-patent business would be a tax-free spin-off, the person added.

Read Also: Pfizer gets USFDA nod for biosimilar to Rituximab

Last year, Pfizer said it was planning to reorganize into three units, separating its consumer healthcare business.

The restructuring will allow the company to evaluate its businesses better and could result in selling or spinning off its off-patent drugs, Wall Street analysts earlier said.

The Wall Street Journal first reported the talks between the companies on Saturday.

Pfizer and Mylan did not immediately respond to requests for comment.

Read Also: Elizabeth Warren asks former USFDA chief Gottlieb to QUIT Pfizer board